Current stock page

Catalysts

ERAS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ERASErasca, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$15.66−$0.12 (−0.76%)

Latest quote

  • Momentum
    67
  • Value
    —
  • Quality
    65
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 11, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 61/100

Momentum 67/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 27.42%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 67/100AIQ Edge 10/10 Sector Leader
Beat rate
38%
3 of 8 reported periods
Average surprise
-56.7%
Across covered historical reports
Latest result
-15.3%
Nov 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 12, 2026—-$0.13-$0.15-15.3%——
Aug 12, 2026—-$0.11-$0.14-25.7%——
May 11, 2026—-$0.11-$0.60-438.0%——
Mar 12, 2026—-$0.11-$0.10+9.1%——
Nov 12, 2025—-$0.11-$0.11+0.0%——
Aug 12, 2025—-$0.12-$0.12+0.0%——
May 13, 2025—-$0.12-$0.11+8.3%——
Mar 20, 2025—-$0.12-$0.11+8.3%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
7
Buy
2
Hold
12-month analyst target
—
— versus current price
Based on 9 analyst observations. Targets are estimates, not predictions.
No analyst target path in this snapshot.
Low target
—
—
Average target
—
—
High target
—
—

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 11, 2027

Next known earnings or reporting date.

EPS estimate-$0.13

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score67

Where event reaction would show up first.

AIQ score61/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
9

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Oct 15, 2026

Erasca, Inc: The Discount RevMed? (NASDAQ:ERAS)

Erasca targets the KRAS inhibitor market with early cancer data, Fast Track status, and 2027 trials ahead. Click to read this latest analysis of ERAS stock.

seekingalpha.com · Oct 5, 2026

Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower (NASDAQ:ERAS)

Erasca is a funded RAS-oncology fast follower with ~$1B liquidity. Click for more on ERAS stock.

gurufocus.com · Sep 17, 2026

Erasca Inc (ERAS) Surges with 312.9% YTD Gain Amid Unprofitable Status and Mixed Ownership Signals

On September 17, 2026, mid-cap healthcare stock Erasca Inc (NASDAQ: ERAS) continues to attract attention with a remarkable year-to-date price increase of 312.90

seekingalpha.com · Sep 15, 2026

Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Erasca, Inc. (ERAS) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsJonathan Lim - Co-Founder,...

insidermonkey.com · Sep 4, 2026

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma.

Open full news and sentiment

ERAS Catalysts FAQ

What are the next catalysts for ERAS stock?

ERAS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ERAS stock?

Upcoming events that could move ERAS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ERAS's next earnings report affect the stock?

ERAS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ERAS stock higher?

ERAS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ERAS stock?

ERAS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.